Sobrevilla-Calvo PJ, Avilés-Salas A, Cortés-Padilla DE, Rivas-Vera S

Idioma: Español
Referencias bibliográficas: 50
Paginas: 187-192
Archivo PDF: 163.89 Kb.

RESUMEN

Introducción: La enfermedad de Castleman es una entidad patológica poco comprendida, descrita originalmente en pacientes europeos. Informamos nuestra experiencia con esta entidad clinicopatológica en pacientes del Instituto Nacional de Cancerología de la Ciudad de México. Material y métodos: Analizamos retrospectivamente los expedientes de pacientes con enfermedad de Castleman de 1996 a 2003. La enfermedad fue monocéntrica si había solo un ganglio o multicéntrica si se encontraba linfoadenopatía generalizada. Además, se dividió en las variantes histológicas hialinovascular y de células plasmáticas. Resultados: Once pacientes con enfermedad de Castleman fueron diagnosticados en el periodo referido, seis tenían enfermedad monocéntrica y cinco multicéntrica. La mediana de seguimiento fue de 40 meses. Todos los pacientes con enfermedad monocéntrica tenían la variante hialinovascular. De los cinco con multicéntrica, cuatro tenían la variante de células plasmáticas y uno la hialinovascular. Cinco pacientes con enfermedad monocéntrica se trataron con cirugía y uno con quimioterapia; al momento de este informe todos permanecían vivos y sin enfermedad. Tres pacientes con enfermedad multicéntrica recibieron quimioterapia y dos, quimioterapia más radioterapia por enfermedad residual; a dos pacientes se les prescribió quimioterapia de segunda línea, con buena respuesta. Dos pacientes con una condición asociada evolucionaron desfavorablemente. Conclusiones: Las características clínicas, patológicas y los resultados del tratamiento son similares a los señalados en otras poblaciones.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Castleman B, Towne VW. Case records of Massachusetts General Hospital. Case 40011. N Engl J Med 1954;250:26-30.

2. Castleman B, Iverson L, Menéndez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956;9:822-830.

3. Frizzera G. Atypical lymphoproliferative disorders: when of age? Virchows Arch A Pathol Anat Histopathol 1993;422:261-263.

4. Abell MR. Lymph nodal hamartoma versus thymic choristoma of pulmonary hilum. Arch Pathol 1957;64:584-588.

5. Zettergren L. Probably neoplastic proliferation of lymphoid tissue (follicular lympho-reticuloma). Report of four cases with a survey of literature. Acta Pathol Microbiol Scand 1961;51:113-126.

6. Harrison EG, Bernatz PE. Angiofollicular mediastinal lymph-node hyperplasia resembling thymoma. Arch Pathol 1963;75:284-292.

7. Tung KS, McCormack LJ. Angiomatous lymphoid hamartoma. Report of five cases of literature. Cancer 1967;20:525-536.

8. Flendrig JA. Benign giant lymphoma: clinicopathologic correlation study. In: Clarck RL, Cumley RS, eds. The Year Book of Cancer. Chicago: Year Book Medical Publishers; 1970. pp. 296-299.

9. Flendrig JA, Schillings PHM. Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 1969;12:119-120.

10. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-683.

11. Bartoli E, Massarelli G, Soggia G, Tanda F. Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 1980;73:423-426.

12. Gaba A, Stein R, Sweet D, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86-90.

13. Kessler E. Multicentric giant lymph node hyperplasia. A report of seven cases. Cancer 1985;56:2446-2451.

14. McCarty MJ, Vukelja SL, Banks PM, Weiss RB. Angiofollicular lymph node hyperplasia (Castleman’s disease). Cancer Treat Rev 1995;21:291-310.

15. Peterson B, Frizzera G. Multicentric Castleman’s Disease. Semin Oncol 1993;20:636-647.

16. Francis ND, Hollowood K, Gabriel R. Angiofollicular lymph node hyperplasia. J Clin Pathol 1988;41:353-354.

17. Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital. Case 10-1987. N Engl J Med 1987;316:606-618.

18. Isaacson PG. Castleman’s disease. Histopathology 1989;14:429-432.

19. Yabuhara A, Yanagisawa M, Murata T, Kawai H, Komiyama A, Akabane T, et al. Giant lymph node hyperplasia (Castleman’s disease) with spontaneous production of high levels of B-cell differentiation factor activity. Cancer 1989;63:260-265.

20. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989;74:1360-1367.

21. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 1990;86:592-599.

22. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin 6 in Castleman’s disease. Blood 1991;78:2923-2930.

23. Katano H, Sata T. An attractive relation of human herpesvirus-8 with multicentric Castleman’s disease. Intern Med 1999;38:221-222.

24. Hayashi M, Aoshiba K, Shimada M, Izawa Y, Yasui S, Nagai A. Kaposi’s sarcoma-associated herpesvirus infection in the lung in multicentric Castleman’s disease. Intern Med 1999;38:279-282.

25. Shahidi H, Myers JL, Kvale PA. Castleman’s disease. Mayo Clin Proc 1995;70:969-977.

26. Frizzera G. Castleman’s disease and related disorders. Semin Diagn Pathol 1988;5:346-364.

27. Frizzera G. Castleman’s disease: more questions than answers. Hum Pathol 1985;16:202-205.

28. Seco JL, Velasco F, Manuel JS, Serrano SR, Tomas L, Velasco A. Retroperitoneal Castleman’s disease. Surgery 1992;112:850-855.

29. Menke D, Camoriano J, Banks PM. Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, and plasma cell types of disease by morphometric and clinical analysis. Mod Pathol 1992;5:525-530.

30. Levan T, Clifford S, Staren E. Castleman’s tumor masquerading as a pancreatic neoplasm. Surgery 1989;106:884-887.

31. Humpherys SR, Holley KE, Smith LH, McIlrath DC. Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic sindrome. Mayo Clin Proc 1975;50:317-321.

32. Shroff VJ, Gilchrist BF, DeLuca FG, McCombs HL, Wesselhoeft CW. Castleman’s disease presenting as a pediatric surgical problem. J Pediatr Surg 1995;30:745-747.

33. Weisenburger DD, De Gowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer 1979;44:457-462.

34. Sethi T, Joshi k, Sharma SC, Gupta BD. Radiation therapy in the management of giant lymph node hyperplasia. Br J Radiol 1990;63:648-650.

35. Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA. Angiofollicular lymph node hyperplasia (Castleman’s disease) in an adolescent female. Clinical and immunologic findings. Cancer 1991; 68:1365-1372.

36. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985;16:162-172.

37. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-1216.

38. Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-717.

39. Frizzera G, Banks PM, Massarelli G, Rosai J. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: pathological findings in 15 patients. Am J Surg Pathol 1983;7:211-231.

40. Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore P, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases. Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman´s disease. Am J Pathol 2000;156: 743-749.

41. Deloose STP, Smit LA, Pals FT, Kersten M-J, Van Noesel CJM, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIVrelated solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia 2005;19:851-855.

42. Cesarman E, Knowles DM. Kaposi’s sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Semin Diag Pathol 1997;14:54-66.

43. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. VHSK is associated with a plasmablastic variant of Castleman disease that is linked to VHSK positive plamablastic lymphoma. Blood 2000;95:1406-1412.

44. Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N, Diss TC, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-2336.

45. Engels EA, Pittaluga S, Whitby D, Rabkin C, Aoki Y, Jaffe ES, et al. Immunoblastic lymphoma in persons with AIDS-associated Kaposi’s sarcoma: a role for Kaposi’s sarcoma-associated herpervirus. Mod Pathol 2003;16:424-429.

46. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman’s disease. Ann Intern Med 1998;128:657-662.

47. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92:670-676.

48. Ushio T, Yoshimura K, Kojima A, Tai H, Hanzawa T, Itsubo K, et al. A case of Castleman’s disease that recurred nine years after initial surgical removal. Nihon Kyobu Shikkan Gakkai Zasshi 1994;32:1175-1178.

49. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.

50. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386-391.